TipRanks
Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks
📊
AI Sentiment
Positive
7/10
- Home
- IKT
as of 02-26-2026 3:53pm EST
$2.07
$0.07
-3.10%
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 201.3M | IPO Year: | 2020 |
| Target Price: | $6.00 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.40 | EPS Growth: | 67.51 |
| 52 Week Low/High: | $1.33 - $2.58 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | -100.00% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -5.35 | Index: | N/A |
| Free Cash Flow: | -19148067.0 | FCF Growth: | N/A |
AI-Powered IKT Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 21 hours ago
AI Recommendation
hold
Model Accuracy: 68.32%
68.32%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Inhibikase Therapeutics Inc. News
IKT Breaking Stock News: Dive into IKT Ticker-Specific Updates for Smart Investing
Compare IKT vs Leading Stocks
See how IKT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IKT Inhibikase Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.